Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-366P (RNA, U6 small nuclear 366, pseudogene) is a non-coding RNA classified as a pseudogene derived from the U6 small nuclear RNA (snRNA) family, not typically considered a direct therapeutic target but possibly involved in regulatory non-coding RNA processes associated with its parental U6 gene. RNU6-366P is a human non-coding RNA pseudogene located on chromosome 14, annotated across standard genomic databases (ENSG00000201097, NCBI 106481294). It is derived from U6 small nuclear RNA, a core component of the spliceosome—the molecular machine responsible for removing introns from pre-mRNA in eukaryotic cells. While U6 snRNA itself is crucial for splicing catalysis and highly conserved, pseudogenes like RNU6-366P do not encode active snRNA molecules, and their direct functional relevance is uncertain. However, pseudogenes may, in some contexts, affect gene expression through various non-coding RNA-mediated mechanisms (e.g., miRNA decoy, double-stranded regulatory RNAs). There is no evidence for RNU6-366P as a direct drug target, receptor, enzyme, or biomarker; it is catalogued to clarify the landscape of non-coding regulatory elements in the genome. Key facts: RNU6-366P is a non-protein-coding pseudogene, not a direct therapeutic target nor known to participate actively in disease pathology or treatment, but belongs to a large family of snRNA pseudogenes that can play indirect roles in gene regulation.
Not applicable; there are no drugs targeting this pseudogene and no direct mechanism of action reported
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 366, pseudogene (RNU6-366P).